Brooks Laboratories Limited (IN:BROOKS)

:BROOKS

BROOKS

Brooks Laboratories Limited

RESEARCH TOOLSreports

Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

1 Followers

BROOKS Stock Chart & Stats

₹123.65

-₹3.80(-2.00%)

At close: Jan 09 4:00 PM EST

₹123.65

-₹3.80(-2.00%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹165.95

Previous CloseN/A

Volume3.81K

Average Volume (3M)2.20K

Market Cap

₹1.45B

Enterprise Value₹1.54B

Total Cash (Recent Filing)₹18.03M

Total Debt (Recent Filing)₹78.33M

Price to Earnings (P/E)10.7

Beta1.67

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.97

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)3.42

Price to Sales (P/S)4.06

P/FCF Ratio-3.45K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improving Leverage And Debt ReductionA declining debt-to-equity ratio from reduced total debt strengthens financial flexibility and lowers interest expense over the medium term. This improved leverage profile gives management more runway to invest in operations or weather losses without immediate refinancing pressure, supporting durability.

Recovery In Revenue GrowthA return to positive top-line growth (15.4% reported) after prior declines suggests demand stabilization and revenue momentum. Sustained revenue recovery helps absorb fixed costs, supports scale economies, and is a prerequisite for durable margin expansion and eventual profitability if maintained.

Improved EBIT/EBITDA MarginsRising operating margins indicate better cost control or higher-margin sales mix. Durable improvements in EBIT/EBITDA increase the company's ability to convert revenue to operating cash, reduce reliance on external funding, and create a clearer path from recovery to sustainable profitability.

Bears Say

Persistent Net Losses And Negative ROESustained net losses that produce negative ROE erode shareholder equity and constrain reinvestment. Over months this limits retention of earnings, reduces internal funding for growth or R&D, and makes the company more dependent on external capital, raising execution risk.

Multi-year Negative Operating And Free Cash FlowProlonged negative operating and free cash flow creates liquidity strain and increases reliance on debt or equity raises. Even with slight 2025 improvement, persistent cash deficits limit capacity for capex, working capital needs, and strategic investments, making long-term recovery fragile.

Revenue And Gross Margin VolatilityVolatile revenue and gross margins make forecasting, pricing, and cost planning difficult, undermining long-term margin sustainability. Such instability can hamper supplier/customer relationships and complicate execution of strategic initiatives, prolonging the path to consistent profits.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

8M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹165.95 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹1.45B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Jun 01, 2026 which is in 11 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on Feb 06, 2026. The company reported ₹1.867 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.867.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of ₹1.867 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.747%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.